Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

The AI-fo­cused biotech in­sitro has laid off 22% of its work­force, the com­pa­ny said in a Thurs­day state­ment. Found­ed ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.

Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...